Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.

Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A.

J Bone Miner Res. 2019 Jun 24. doi: 10.1002/jbmr.3735. [Epub ahead of print]

PMID:
31233639
2.

Parity and lactation are not associated with incident fragility fractures or radiographic vertebral fractures over 16 years of follow-up: Canadian Multicentre Osteoporosis Study (CaMos).

Cooke-Hubley S, Gao Z, Mugford G, Kaiser SM, Goltzman D, Leslie WD, Davison KS, Brown JP, Probyn L, Lentle B, Prior JC, Kovacs CS.

Arch Osteoporos. 2019 Apr 29;14(1):49. doi: 10.1007/s11657-019-0601-6.

PMID:
31037359
3.

The Radiology of Osteoporotic Vertebral Fractures Revisited.

Lentle B, Koromani F, Brown JP, Oei L, Ward L, Goltzman D, Rivadeneira F, Leslie WD, Probyn L, Prior J, Hammond I, Cheung AM, Oei EH; Vertebral Fracture Research Groups of the CaMos, STOPP, and Rotterdam Studies.

J Bone Miner Res. 2019 Mar;34(3):409-418. doi: 10.1002/jbmr.3669. Epub 2019 Feb 27. Review.

PMID:
30645770
4.

Gene-environment interactions in Paget's disease of bone.

Numan MS, Jean S, Dessay M, Gagnon E, Amiable N, Brown JP, Michou L.

Joint Bone Spine. 2019 May;86(3):373-380. doi: 10.1016/j.jbspin.2018.12.007. Epub 2018 Dec 27.

5.

Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population.

Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie LG, Brown JP.

J Bone Miner Res. 2018 Nov;33(11):1956-1966. doi: 10.1002/jbmr.3526. Epub 2018 Jun 29.

PMID:
29924429
6.

Molecular effect of an OPTN common variant associated to Paget's disease of bone.

Silva IAL, Conceição N, Gagnon É, Brown JP, Cancela ML, Michou L.

PLoS One. 2018 May 21;13(5):e0197543. doi: 10.1371/journal.pone.0197543. eCollection 2018.

7.

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.

McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A.

J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22.

8.

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.

Dempster DW, Brown JP, Fahrleitner-Pammer A, Kendler D, Rizzo S, Valter I, Wagman RB, Yin X, Yue SV, Boivin G.

J Clin Endocrinol Metab. 2018 Jul 1;103(7):2498-2509. doi: 10.1210/jc.2017-02669.

9.

Response to Dr Lamy and Dr Gonzalez-Rodriguez.

Cummings SR, Ferrari S, Brown JP, Wang AT.

J Bone Miner Res. 2018 Mar;33(3):548. doi: 10.1002/jbmr.3403. No abstract available.

10.

Osteoporotic fractures and obesity affect frailty progression: a longitudinal analysis of the Canadian multicentre osteoporosis study.

Gajic-Veljanoski O, Papaioannou A, Kennedy C, Ioannidis G, Berger C, Wong AKO, Rockwood K, Kirkland S, Raina P, Thabane L, Adachi JD; CaMos Research Group.

BMC Geriatr. 2018 Jan 5;18(1):4. doi: 10.1186/s12877-017-0692-0.

11.

Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with Paget's disease of bone.

Laurier E, Amiable N, Gagnon E, Brown JP, Michou L.

BMC Med Genet. 2017 Nov 16;18(1):133. doi: 10.1186/s12881-017-0495-3.

12.

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.

Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP.

J Bone Miner Res. 2018 Feb;33(2):190-198. doi: 10.1002/jbmr.3337. Epub 2017 Nov 22.

13.

Antiresorptives: Safety Concerns-Clinical Perspective.

Brown JP.

Toxicol Pathol. 2017 Oct;45(7):859-863. doi: 10.1177/0192623317737066. Epub 2017 Oct 24. Review.

PMID:
29065818
14.

Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study.

Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA.

J Bone Miner Res. 2018 Feb;33(2):298-306. doi: 10.1002/jbmr.3309. Epub 2017 Nov 15.

15.

Effect of genetic variants of OPTN in the pathophysiology of Paget's disease of bone.

Silva IAL, Conceição N, Gagnon É, Caiado H, Brown JP, Gianfrancesco F, Michou L, Cancela ML.

Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):143-151. doi: 10.1016/j.bbadis.2017.10.008. Epub 2017 Oct 6.

16.

Ly6Chigh monocytes facilitate transport of Murid herpesvirus 68 into inflamed joints of arthritic mice.

LeBel M, Egarnes B, Brunet A, Lacerte P, Paré A, Lacroix S, Brown JP, Gosselin J.

Eur J Immunol. 2018 Feb;48(2):250-257. doi: 10.1002/eji.201747048. Epub 2017 Nov 22.

17.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A.

Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26.

PMID:
28755782
18.

Comparative Analysis of the Radiology of Osteoporotic Vertebral Fractures in Women and Men: Cross-Sectional and Longitudinal Observations from the Canadian Multicentre Osteoporosis Study (CaMos).

Lentle BC, Berger C, Probyn L, Brown JP, Langsetmo L, Fine B, Lian K, Shergill AK, Trollip J, Jackson S, Leslie WD, Prior JC, Kaiser SM, Hanley DA, Adachi JD, Towheed T, Davison KS, Cheung AM, Goltzman D; CaMos Research Group.

J Bone Miner Res. 2018 Apr;33(4):569-579. doi: 10.1002/jbmr.3222. Epub 2017 Aug 7.

19.

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S.

Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22.

PMID:
28546097
20.

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass.

Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, Brown JP, Langdahl BL, Yan C, Grauer A, Libanati C.

J Bone Miner Res. 2017 Sep;32(9):1956-1962. doi: 10.1002/jbmr.3176. Epub 2017 Jun 26.

Supplemental Content

Loading ...
Support Center